The short version of Thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Exopolysaccharides === Exopolysaccharides (also sometimes abbreviated EPS; EPS sugars thereafter) are the sugar-based parts of EPS. Microorganisms synthesize a wide spectrum of multifunctional polysaccharides including intracellular polysaccharides, structural polysaccharides and extracellular polysaccharides or exopolysaccharides. Exopolysaccharides generally consist of monosaccharides and some non-carbohydrate substituents (such as acetate, pyruvate, succinate, and phosphate). Exopolysaccharides are secreted from microorganisms including microalgae into the surrounding environment during their growth or propagation. They can either be loosely attached to the cell wall or excreted into the environment. Many microalgae, especially a variety of red algae and cyanobacteria, are producers of structurally diverse exopolysaccharides. Additionally, exopolysaccharides are involved in cell-to-cell interactions, adhesion, and biofilm formation. Exopolysaccharides are widely used in the food industry as thickeners and gelling additives, which improve food quality and texture. Currently, exopolysaccharides have received much attention for their antibacterial, anti-oxidative, and anticancer properties, which lead to the development of promising pharmaceutical candidates. Since exopolysaccharides are released into the culture medium, they can be easily recovered and purified. Different strategies used for the economical extraction and other downstream processing were discussed in a chapter of the referenced book.
In investigating the regulation of muscle protein production, they observed that neither mRNA nor antisense RNA injections had an effect on protein production, but double-stranded RNA successfully silenced the targeted gene. As a result of this work, they coined the term RNAi. This discovery represented the first identification of the causative agent for the phenomenon. Fire and Mello were awarded the 2006 Nobel Prize in Physiology or Medicine.
=== Other functions === Cholesterol translocation from outer to the inner mitochondrial membrane Activates mitochondrial cholesterol side-chain cleavage Import protein into mitochondrial matrix Anticoagulant function Modulates α-synuclein - malfunction of this process is thought to be a cause of Parkinson's disease.
=== Social services === On November 15, 2018, the government announced it was eliminating three watchdog legislative offices, including the child and youth advocate. One of the biggest cuts, announced in the 2019 budget, was the $1 billion cut—over four years—to the Ministry of Community and Social Services. In February 2019, the government had announced changes to the Ontario Autism Program, which had over 20,000 children on a waiting list. Under Minister MacLeod and Fee, changes were made in "how children qualified, based on age and family income". During the revamping of the Program, support for children already receiving service, was clawed back which meant that families had to pay most of the bills for "very expensive behavioural therapies." This "outraged those in the autism community". The protests included a "huge rally at Queen's Park that could be heard inside the legislature and inundated Tory MPPs and Social Services Minister Lisa MacLeod with complaints." In response, the Ford government "scrambled to pour more money into the program and in early May [2019] announced consultations that would help shape further reforms to the system, moving toward one based on need." The Hamilton Spectator said that of all the "policy snafus", the funding of services for families of children with autism, was the one that bothered Ford the most.
Sources: en.wikipedia.org
== Invertebrates == It is less common to find examples of dedifferentiation (due to a lack of regenerative ability) in most invertebrates. This brief example outlines dedifferentiation in an invertebrate species, and interestingly involves the Msx pathway, as detailed above in the mechanisms section.
== Compo recipes == A basic compo recipe can have many variations. Some understanding of what each ingredient is doing helps when adjusting the basic recipe, starting with the four essential ingredients:
Grizard, G; Sion, B; Bauchart, D; Boucher, D (31 March 2000). "Separation and quantification of cholesterol and major phospholipid classes in human semen by high-performance liquid chromatography and light-scattering detection". Journal of Chromatography B: Biomedical Sciences and Applications. 740 (1): 101–7. doi:10.1016/S0378-4347(00)00039-6. PMID 10798299. SUNY Podcast – Semen study results Hyena, Hank (August 21, 2000). "The quest for sweet semen". Salon.
== External links == "The Cheminformatics and QSAR Society". Retrieved 2009-05-11. "The 3D QSAR Server". Retrieved 2011-06-18. Verma, Rajeshwar P.; Hansch, Corwin (2007). "Nature Protocols: Development of QSAR models using C-QSAR program". Protocol Exchange. doi:10.1038/nprot.2007.125. Archived from the original on 2007-05-01. Retrieved 2009-05-11. A regression program that has dual databases of over 21,000 QSAR models "QSAR World". Archived from the original on 2009-04-25. Retrieved 2009-05-11. A comprehensive web resource for QSAR modelers Chemoinformatics Tools Archived 2017-07-04 at the Wayback Machine, Drug Theoretics and Cheminformatics Laboratory Multiscale Conceptual Model Figures for QSARs in Biological and Environmental Science
=== 13 February === At least 30 people were reported killed in RSF attacks on al-Jamalab and Na'ima in White Nile State. Fifteen others drowned on the White Nile river while they were boarding a boat to escape the attacks.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.